Monthly Archives

February 2020

Press Release

Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board

SAN DIEGO– (BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board.   Dr. Peoples has served his…
Calidi Biotherapeutics
February 27, 2020
Press Release

Calidi Biotherapeutics Announces Appointment of Biotech Veteran Heehyoung Lee to Board of Directors

SAN DIEGO– (BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, Heehyoung Lee, Managing Partner at LumeBio, to its board of directors. Dr. Lee brings over 15…
Calidi Biotherapeutics
February 20, 2020
Press Release

Calidi Biotherapeutics Presents Data at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, presented pre-clinical data on their lead oncolytic virus candidate SNV1 (allogeneic adipose derived mesenchymal stem cells loaded with tumor selective CAL1 vaccinia virus) in a poster…
Calidi Biotherapeutics
February 13, 2020
Press Release

Calidi Biotherapeutics Announces Abstract Acceptance For Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced the acceptance of an abstract for presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium, which is being held February 6  to February 8, 2020, at the Rosen…
Calidi Biotherapeutics
February 3, 2020